Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of VX-634 in Healthy Volunteers
NCT05579431Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-634 in alpha-1 antitrypsin deficiency (AATD) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Oct 2022; status: completed.
02
Drugs
VX-634
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05579431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579431.